SEC Comment Letter for Lifevantage Corp (LFVN) (CIK 0000849146) (LFVN) — Apr 4, 2023

Lifevantage Corp (LFVN) (CIK 0000849146)
Date: April 4, 2023 · CIK: 0000849146 · Accession: 0000000000-23-003366

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-271061

Date

April 4, 2023

Author

Steven R. Fife

Form

UPLOAD

Company

Lifevantage Corp (LFVN) (CIK 0000849146)

Letter

United States securities and exchange commission logo April 4, 2023 Steven R. Fife President and Chief Executive Officer LifeVantage Corporation 3300 Triumph Blvd., Suite 700 Lehi, UT 84043 Re:LifeVantage Corporation Registration Statement on Form S-3 Filed March 31, 2023 File No. 333-271061 Dear Steven R. Fife: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kirt W Shuldberg, Esq.

Show Raw Text

United States securities and exchange commission logo
April 4, 2023
Steven R. Fife
President and Chief Executive Officer
LifeVantage Corporation
3300 Triumph Blvd., Suite 700
Lehi, UT 84043
Re:LifeVantage Corporation
Registration Statement on Form S-3
Filed March 31, 2023
File No. 333-271061
Dear Steven R. Fife:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Kirt W Shuldberg, Esq.

SecProbe.io